within Pharmacolibrary.Drugs.ATC.J;

model J06BD08
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.1166666666666666e-06,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00298,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0022400000000000002,
    k12             = 0.267,
    k21             = 0.267
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J06BD08</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Nirsevimab is a monoclonal antibody used for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants. It binds to the RSV fusion protein, preventing viral entry into host cells. Approved in several regions including the US and EU for prevention of RSV in neonates and infants entering their first RSV season.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics were evaluated in healthy neonates and infants (≤1 year old), both preterm and term, who received a single intramuscular dose of nirsevimab.</p><h4>References</h4><ol><li><p>Domachowske, J, et al., &amp; Villafana, T (2024). Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children. <i>Pediatrics</i> 154(4) –. DOI:<a href=\"https://doi.org/10.1542/peds.2024-066508\">10.1542/peds.2024-066508</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39257380/\">https://pubmed.ncbi.nlm.nih.gov/39257380</a></p></li><li><p>Simões, EAF, et al., &amp; Villafana, T (2023). Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. <i>The Lancet. Child &amp; adolescent health</i> 7(3) 180–189. DOI:<a href=\"https://doi.org/10.1016/S2352-4642(22)00321-2\">10.1016/S2352-4642(22)00321-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36634694/\">https://pubmed.ncbi.nlm.nih.gov/36634694</a></p></li><li><p>Domachowske, J, et al., &amp; Villafana, T (2022). Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. <i>The New England journal of medicine</i> 386(9) 892–894. DOI:<a href=\"https://doi.org/10.1056/NEJMc2112186\">10.1056/NEJMc2112186</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35235733/\">https://pubmed.ncbi.nlm.nih.gov/35235733</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J06BD08;
